Manish Goel

About Manish Goel

SEBI Registered Research Analyst • Chartered Accountant

377 Articles Published

Manish Goel is a Chartered Accountant, SEBI Registered Research Analyst, and founder of Manish Goel PMS. A full-time value investor since 2010, he has helped thousands of investors build long-term wealth through quality stock picking and disciplined fundamental analysis.

Facebook X (Twitter) Instagram YouTube LinkedIn

March 17, 2026

Bar chart titled The Coffee Can Portfolio showing yearly values FY20–FY25: 28, 26, 22, 18, 14, with FY25 value 11 in a green bar highlight

The Coffee Can Portfolio: Why Doing Nothing Can Make You Rich

MGMANISH GOEL PMS☰ HomePast PerformanceServicesMedia & PressBlogsAwards WhatsApp · 7380122211 VALUE INVESTING · BLOG The Coffee Can Portfolio: Why Doing Nothing Can Make You Rich ← […]

March 16, 2026

Header with title 'Titan Biotech 50x Deep Dive' and a horizontal bar chart for FY20–FY25; values 28, 26, 22, 18, 14, 11; FY25 bar is green.

Titan Biotech 50x Deep Dive: Complete Value Investing Analysis — How ₹8 Became ₹400

MGMANISH GOEL PMS☰ HomePast PerformanceServicesMedia & PressBlogsAwards WhatsApp · 7380122211 VALUE INVESTING · BLOG Titan Biotech 50x Deep Dive: Complete Value Investing Analysis — How ₹8 […]

March 16, 2026

Titan Biotech header with subtitle; horizontal bar chart shows yearly values from FY20 to FY25: FY20 28, FY21 26, FY22 22, FY23 18, FY24 14, FY25 11 (green).

Titan Biotech: From ₹8 to ₹400 — The 50x Multibagger Story | Value Investing #Shorts

MGMANISH GOEL PMS☰ HomePast PerformanceServicesMedia & PressBlogsAwards WhatsApp · 7380122211 VALUE INVESTING · BLOG Titan Biotech: From ₹8 to ₹400 — The 50x Multibagger Story | […]

March 16, 2026

Hero section: article title about Rupee until ₹93/$; subtitle in italics; includes a horizontal bar chart showing FY20–FY25 values, with the final bar highlighted in green (11 in FY25).

Rupee at ₹93/$ — Why This Is a Golden Opportunity for Pharma & Biotech Investors

The Indian Rupee has depreciated to ~93 per US Dollar. While headlines scream doom, smart investors see this as a powerful tailwind for India's $30B+ pharma export engine. India is the Pharmacy of the World — and a weaker rupee makes it even more competitive. Here's why pharma & biotech stocks are the biggest beneficiaries.